Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/52830
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJava A.-
dc.contributor.authorBomback A.S.-
dc.contributor.authorKavanagh D.-
dc.contributor.authorRemuzzi G.-
dc.contributor.authorSunder-Plassmann G.-
dc.contributor.authorKanellis J.-
dc.contributor.authorDaina E.-
dc.contributor.authorWalker P.D.-
dc.contributor.authorWang Z.-
dc.contributor.authorAhmad Z.-
dc.contributor.authorFakhouri F.-
dc.date.accessioned2025-01-06T02:50:45Z-
dc.date.available2025-01-06T02:50:45Z-
dc.date.copyright2024-
dc.date.issued2024-11-13en
dc.identifier.citationJournal of the American Society of Nephrology. Conference: Kidney Week 2024. San Diego, CA United States. 35(pp 1080), 2024. Date of Publication: 2024.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/52830-
dc.description.abstractBackground: Pegcetacoplan (Peg; targeted C3/C3b inhibitor) may prevent kidney damage in C3G and primary IC-MPGN. NOBLE (NCT04572854) randomized 13 patients with post-transplant recurrent C3G or primary IC-MPGN. At week 12, Peg was well tolerated and showed improvements in histologic, clinical, and biomarker parameters of disease. Method(s): We conducted a post-hoc analysis of 9 NOBLE patients treated with subcutaneous Peg 1080 mg twice weekly plus standard of care for 52 weeks; of these, treatment completers had >80% compliance (n=7). Result(s): At week 52, 5/9 (55.6%) patients had reduced C3c staining (p=0.0423 vs baseline). 7/9 (77.8%) had decreased activity score compared to baseline and 2/8 (25%) had absent electron microscopy deposits at week-52 biopsy. Patients with >1 g/g proteinuria at baseline had a median 56.4% decrease in proteinuria (Table). 7/9 (77.8%) patients had stable/improved estimated glomerular filtration rate, and 8/9 (88.9%) had both increased serum C3 and decreased sC5b-9. No meningitis cases, graft losses, or deaths were reported. Non-serious rejection episodes were reported for 2/9 (22.2%) patients. 1 patient (11.1%) discontinued for serious adverse event of weight loss. Conclusion(s): By inhibiting the breakdown of C3, Peg achieved meaningful histology improvements for 8/9 (88.9%) patients while also improving disease parameters, increasing serum C3, and decreasing plasma sC5b-9. The Phase 3 VALIANT (NCT05067127) trial will further evaluate the safety and efficacy of Peg in patients with native kidney or post-transplant C3G or primary IC-MPGN.-
dc.relation.ispartofJournal of the American Society of Nephrology-
dc.subject.meshelectron microscopy-
dc.subject.meshglomerulopathy-
dc.subject.meshgraft failure-
dc.subject.meshhistology-
dc.subject.meshmembranoproliferative glomerulonephritis-
dc.subject.meshmeningitis-
dc.subject.meshproteinuria-
dc.titlePegcetacoplan for post-transplant recurrent c3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN) in noble: 52-week patient evolution.-
dc.typeConference Abstract-
dc.identifier.affiliationNephrology-
dc.description.conferencenameKidney Week 2024-
dc.description.conferencelocationSan Diego, CA, United States-
dc.type.studyortrialClinical trial-
local.date.conferencestart2024-10-23-
dc.identifier.institution(Java) Washington University in St Louis School of Medicine, St Louis, MO, United States-
dc.identifier.institution(Bomback) Columbia University, Irving Medical Center, New York, NY, United States-
dc.identifier.institution(Kavanagh) Newcastle University, Newcastle upon Tyne, United Kingdom-
dc.identifier.institution(Remuzzi, Daina) Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy-
dc.identifier.institution(Sunder-Plassmann) Medizinische Universitat Wien, Vienna, Austria-
dc.identifier.institution(Kanellis) Monash Medical Centre, Clayton, VIC, Australia-
dc.identifier.institution(Walker) Arkana Laboratories, Little Rock, AR, United States-
dc.identifier.institution(Wang, Ahmad) Apellis Pharmaceuticals Inc, Waltham, MA, United States-
dc.identifier.institution(Fakhouri) Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland-
local.date.conferenceend2023-06-06-
dc.identifier.affiliationmh(Kanellis) Monash Medical Centre, Clayton, VIC, Australia-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeConference Abstract-
Appears in Collections:Conferences
Show simple item record

Page view(s)

20
checked on Mar 13, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.